| 79.97 0 (0%) | 02-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Inari Medical, Inc. is a medical technology firm focused on creating, producing, promoting, and distributing devices for the minimally invasive management of venous conditions within the United States. Their product portfolio includes ClotTriever, a mechanical thrombectomy solution designed to extract significant clots from major blood vessels, specifically targeting deep vein thrombosis. Another key offering is FlowTriever, a substantial catheter-based aspiration and mechanical thrombectomy system, which addresses pulmonary embolism. The company also provides FlowSaver; FlowStasis, a large-bore suture retention device to manage venous access points; and FlowTriever 2, an enhanced version with a new disk design for efficiently capturing wall-adherent clots and reducing procedure time. Founded in 2011, the company was initially known as Inceptus Newco1 Inc. before rebranding as Inari Medical, Inc. in September 2013. Its corporate headquarters are located in Irvine, California.
Tue, 02 Jun 2026
Inari Medical Inc stock (US45332Y1092): Shares ease after May volatility as investors await next ear - AD HOC NEWS
Sat, 16 May 2026
Inari Medical stock (US45332Y1092): Stryker deal reshapes outlook for thrombectomy specialist - AD HOC NEWS
Wed, 19 Feb 2025
Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment - GlobeNewswire
Wed, 19 Feb 2025
Inari Medical, Inc. (NARI): the Best Performing Healthcare Stock So Far in 2025 - Yahoo Finance
Sat, 15 Feb 2025
Stryker Acquires Inari Medical: A $4.7 Billion Healthcare Merger (SYK, NARI) - tradingcalendar.com
Mon, 06 Jan 2025
Stryker announces definitive agreement to acquire Inari - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|